Adjuvant Treatment with nivolumab in the Prevention of recurrence after curative treatment of Hepatocellular Carcinoma(NIVOLVE)
Phase 2
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- JPRN-UMIN000026648
- Lead Sponsor
- Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1.History of treatment except for hepatic resection of RFA 2.History or present of autoimmune disease 3.History or present of inestitial neumonia 4.History of malignancy 5.Renal falure 6.severe heart disease 7.severe hypertension 8.active infection 9.History of treatment using immunotherapy such as immune checkpoint inhibitor, peptide vaccine, biochemical modulator and Lymphocyte stimulation therapy 10.pregnancy or breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method